Rashmi Vora

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer

Ewan Brown, Kellie A. Charles, Susan Hoare et al. · Annals of Oncology · 2008 · 182 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).

Ignacio Garrido‐Laguna, Brian M. Wolpin, Wungki Park et al. · Journal of Clinical Oncology · 2025 · 39 citations

Medicine, Oncology, Pharmacology +16

6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)

Salman R. Punekar, Dehan Hong, Jia Luo et al. · Journal of Thoracic Oncology · 2025 · 15 citations · Full text

Medicine, Oncology, Pharmacology +12